A breakthrough in the treatment of muscular dystrophy comes in the form of a new drug, which has recently been approved for insurance coverage by the Japanese government. This revolutionary medicine is worth an extraordinary 3 billion yen. Patients suffering from muscular dystrophy in Japan will now have easier access to this potentially life-changing treatment. The decision was made after thorough consideration and extensive clinical trials, signifying a substantial step towards better healthcare services in the country.

This news resonates deeply within Japan where aged population and healthcare accessibility are crucial societal concerns. The Japanese government highly values its healthcare system and strives to make sure it is inclusive and accommodating for all citizens. Presently, a significant focus of the system is to make innovative treatments widely available - a goal that the approval of this new expensive drug for insurance coverage accomplishes.

In the US and EU, high costs are a big obstacle to access to novel treatments. Often, without insurance coverage, these medications could be prohibitively expensive for many patients. Therefore, inclusion of novel drugs in insurance coverage is seen as a critical step towards improving healthcare access and is also a topic of intense debate in these countries.